Saposin-A Derived Peptides with Anti-Angiogenic Activity for Tumor Treatment
Summary
The USPTO published patent application US20260091079A1 by Children's Medical Center Corporation covering Saposin-A derived polypeptides with anti-angiogenic activity. The peptides consist of 9 or fewer amino acid residues containing the active core sequence DWLP. The disclosed invention can be used to inhibit tumor growth and cancer metastasis.
What changed
Children's Medical Center Corporation filed patent application US20260091079A1 claiming compositions and methods using Saposin-A derived polypeptides. The disclosed invention covers polypeptides of 9 or fewer amino acids (preferably 4-6 mers) comprising the DWLP core sequence or variants thereof, demonstrating anti-angiogenic activity useful for treating cancer and inhibiting tumor metastasis. The application includes specific amino acid substitution variants and fusion polypeptide embodiments.
This is a published patent application providing public notice of the claimed intellectual property. Third parties interested in developing similar peptide therapeutics or anti-angiogenic cancer treatments should review the claimed scope for freedom-to-operate considerations. No compliance deadlines or regulatory requirements apply to this publication.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
SAPOSIN-A DERIVED PEPTIDES AND USES THEREOF
Application US20260091079A1 Kind: A1 Apr 02, 2026
Assignee
CHILDREN'S MEDICAL CENTER CORPORATION
Inventors
Randolph S. Watnick
Abstract
Disclosed herein are polypeptides and fusion polypeptides that have anti-angiogenic activity that can be used to inhibit tumor growth and tumor metastasis. The polypeptide consists of 9 or less consecutive amino acid residues (e.g., 8, 7, 6, 5, or 4) comprising the active core amino acid sequence DWLP, or an amino acid substitution variant thereof. Specific amino acid substitutions are disclosed herein. In some embodiments, the peptide consists essentially of 4-6 mers identified as exhibiting the activity of prosaposin A. Also disclosed herein are therapeutic compositions comprising the polypeptides and fusion polypeptides, and their use in the treatment, prevention, and inhibition of angiogenesis-related diseases and disorders such as cancer and cancer metastasis.
CPC Classifications
A61K 38/08 A61K 38/07 A61K 39/39591 A61K 45/06 C07K 5/1019 C07K 5/1021 C07K 7/06 C07K 14/475 C07K 16/00 C12Q 1/6886 G01N 33/5023 G01N 33/575 G01N 33/6893 G01N 33/74 A61K 38/00 A61K 2039/505 C07K 2319/30 C07K 2319/31 C12Q 2600/106 G01N 2800/52
Filing Date
2025-03-26
Application No.
19090844
Named provisions
Related changes
Get daily alerts for ChangeBridge: Patent Apps - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: Patent Apps - Peptides (C07K) publishes new changes.